Access and Utilization of New Antidepressant and Antipsychotic Medications. Appendix C. Interview Respondents


Stakeholder Group Interviews Completed Request for Interview Refused or Unable to Schedule
Federal Government Health Care Financing Administration(now known as Centers for Medicare and Medicaid Services(CMS))
Indian Health Service
  • Navajo Region

Department of Defense (DoD)
Pharmaco-Economic Center
Mental Health Policy Division
Tri-Care Mental Health Benefits

  • Patient Advocacy and Medical Ethics

Pharmacy Division
Veterans Administration
Mental Health Division

State Mental Health Systems Arizona
State Medicaid Programs California
State Correctional Systems New York State  
Pharmaceutical Companies AstraZeneca
  • Government Affairs

Janssen Pharmaceuticals

  • Multiple Divisions

Eli Lilly and Company

  • Multiple Divisions

Glaxo Wellcome

  • Care Management

One Additional Pharmaceutical Company
(Anonymous by Request)

  • Government Affairs
  • Seroquel Marketing

Forest Labs
Solvay Pharmaceuticals

Health Maintenance Organizations (HMOs) Harvard Pilgrim 
Health Partners (MN) 
First Option (NJ) 
Group Health (WA) 
Kaiser Permanente Mid-Atlantic
Aetna US Healthcare, Mid-Atlantic 
Health Options HMO (BCBC, Florida) 
Kaiser Permanente, Northern California 
Kaiser Permanente, Pacific Northwest
Pharmacy Benefit Managers (PBMs) ValueRx/Express Scripts 
PCS Health System 
Prescription Solutions PBM Division of Pacificare (CA) 
Rx Innovations Division of Value/Options 
One Additional PBM (Anonymous by Request)
Behavioral Health Managed Care Organizations (BHMCOs) Magellan 
Value Options
United Behavioral Health
Employers Delta Airlines
William Mercer and Company
Washington Business Group on Health
Consumer and Advocacy Associations National Alliance for the Mentally Ill 
National Mental Health Association
Provider Associations American Academy of Family Physicians
American Psychiatric Association
American College of Physicians

Note: Due to geographic and other scheduling difficulties, it was often necessary to conduct more than one interview with each respondent. As a result, the number of interviews reported in Table I-3 is greater than the number of interviewees.